Home » Healthcare » France Chronic Pain Market

France Chronic Pain Market By Indication (Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, Migraine); By Drug Class (Opioids, Non-Steroidal, Anticonvulsants, Antidepressants, Drug Class 5); By Application (Musculoskeletal, Neuropathy, Oncology, Others); By Technology (Technology 1, Technology 2, Technology 3); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others, Distribution Channel 4, Distribution Channel 5) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
France Chronic Pain Market Size 2023	USD 3,088.37 million
France Chronic Pain Market, CAGR	5.15%
France Chronic Pain Market Size 2032	USD 4,937.10 million

Market Overview

The chronic pain market in France is projected to grow from USD 3,088.37 million in 2023 to USD 4,937.10 million by 2032, at a compound annual growth rate (CAGR) of 5.15%.

The chronic pain market in France is driven by several key factors, including the increasing prevalence of conditions such as arthritis, neuropathic pain, and back pain, as well as the aging population. With a rising number of individuals suffering from chronic pain, the demand for effective pain management solutions is growing. Advancements in pharmacological treatments, such as new analgesics and biologics, alongside the adoption of innovative therapies like neuromodulation and personalized medicine, are contributing to market growth. Additionally, the French government’s efforts to improve healthcare infrastructure and access to pain management services are further supporting market expansion. The growing awareness around the impact of chronic pain on quality of life, along with advancements in digital health technologies and telemedicine for pain management, are shaping market trends. This evolving landscape is expected to drive sustained growth in the France chronic pain market in the coming years.

France’s chronic pain market is geographically diverse, with regional variations in the prevalence of pain conditions and access to treatment. Northern France, particularly urban areas like Paris, Lille, and Lyon, benefits from advanced healthcare infrastructure, offering a high concentration of specialized pain management centers. Southern France, with its aging population and higher incidence of musculoskeletal disorders, sees a growing demand for chronic pain therapies, particularly in cities like Marseille and Nice. In both regions, the integration of digital health tools and non-opioid treatment options is gaining momentum. Key players in the French chronic pain market include global pharmaceutical companies like Abbott Laboratories and Grünenthal, known for their innovative pain management solutions. Additionally, emerging players like Remedee Labs and SUBLIMED are contributing with advanced technologies in neuromodulation and digital health, providing new opportunities in personalized pain management across the country. These companies, along with local healthcare providers, play a pivotal role in shaping the market’s growth.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The France chronic pain market was valued at USD 3,088.37 million in 2023 and is projected to reach USD 4,937.10 million by 2032, growing at a CAGR of 5.15%.
The increasing aging population is a significant driver, contributing to a higher prevalence of chronic pain conditions.
Rising awareness of chronic pain management and advancements in treatment options further fuel market growth.
Concerns over opioid addiction and a shift towards non-opioid therapies are reshaping pain management strategies.
Limited access to care, especially in rural areas, poses a challenge to effective chronic pain treatment.
The northern and southern regions of France dominate the market, with urban centers having better access to specialized care.
Key players like Abbott Laboratories, Grünenthal, Remedee Labs, and SUBLIMED are driving innovation and growth in the chronic pain market.

Market Drivers

Rising Prevalence of Chronic Diseases

Lifestyle factors such as sedentary behavior, poor diet, and increased stress are contributing to the growing prevalence of chronic diseases in France. Conditions like diabetes, cardiovascular disease, and cancer often bring about chronic pain, further driving the demand for pain management solutions. For instance, cardiovascular diseases affected 5.1 million people, diabetes 4.0 million, and cancers 3.3 million in 2019. As more people are diagnosed with these diseases, the number of individuals living with chronic pain increases, placing additional pressure on healthcare systems. This trend is propelling the need for better pain relief treatments, which in turn fuels the chronic pain market.

Aging Population and Increased Healthcare Costs

The aging population in France is a significant driver of the chronic pain market. As the population continues to age, the prevalence of chronic pain conditions, such as arthritis, fibromyalgia, and neuropathic pain, is on the rise. For instance, approximately 20% of the French general population suffers from chronic pain of at least moderate intensity, with the prevalence estimated to affect up to 60% of elderly subjects. This demographic shift contributes to a greater burden on the healthcare system, leading to higher healthcare costs, particularly related to the management of chronic pain. With more elderly individuals requiring long-term pain management, there is an increasing demand for effective treatments, which is expected to accelerate market growth.

Growing Awareness and Demand for Effective Treatments

There is a rising awareness among patients about chronic pain conditions and the available treatment options. As a result, patients are seeking more effective therapies to improve their quality of life and reduce pain-related disabilities. This growing awareness is driving demand for advanced pain management solutions, including pharmacological treatments and innovative devices. Patients are increasingly motivated to pursue treatments that not only alleviate pain but also enhance overall well-being, contributing to the market’s expansion.

Favorable Regulatory Environment and Technological Advancements

The French regulatory environment supports innovation in pain management therapies, encouraging the development of new drugs and devices. Additionally, favorable reimbursement policies for effective treatments further boost market growth. For instance, multidisciplinary and pluriprofessional structures have been developed specifically to better assess and manage the most hard-to-treat chronic pain patients. Technological advancements, such as neuromodulation devices and targeted drug delivery systems, offer innovative solutions for pain relief. Furthermore, the rise of digital health solutions is enhancing patient engagement, improving monitoring, and enabling remote therapy delivery. These factors are expected to play a pivotal role in the continued growth of the chronic pain market in France.

Market Trends

Rising Prevalence and Aging Population Driving Demand for Pain Management

The chronic pain market in France is significantly influenced by demographic shifts and increasing awareness about chronic pain. As the population ages, there is a rise in the incidence of chronic pain conditions such as arthritis, fibromyalgia, and neuropathic pain. This demographic change is putting additional pressure on healthcare systems to provide long-term pain management solutions. Simultaneously, there is a growing awareness of the detrimental effects chronic pain has on an individual’s quality of life, further driving demand for effective treatments. Patients are now more informed about available therapies and are increasingly seeking solutions that not only alleviate pain but also improve overall well-being. This awareness, combined with the expanding aging population, is set to propel the demand for advanced pain management solutions in the coming years.

Shift Towards Non-Opioid Therapies and Technological Advancements

Another key trend in the France chronic pain market is the growing shift away from opioid-based treatments due to concerns over addiction and overdose. As the opioid crisis continues to affect global health, there has been a concerted effort to explore non-opioid pain management strategies. For instance, the French National Authority for Health (HAS) recommends non-opioid treatments as first-line therapy for chronic pain. This includes a focus on non-pharmacological interventions such as physical therapy, acupuncture, and mindfulness practices, which are gaining popularity as part of a holistic approach to pain management. Moreover, advancements in digital health integration are contributing to this shift. Digital tools enable remote monitoring of pain symptoms and allow for personalized treatment plans, providing patients with greater control over their pain management. Telehealth consultations are also improving access to pain management services, particularly in underserved areas. For example, the use of teleconsultations in France increased significantly during the COVID-19 pandemic, with over 19 million teleconsultations conducted in 2020. Furthermore, innovations in treatment approaches, such as neuromodulation therapies (spinal cord stimulation and peripheral nerve stimulation) and targeted therapies like gene therapies and monoclonal antibodies, are offering new avenues for chronic pain relief. These developments align with the growing emphasis on value-based healthcare, where patient outcomes and cost-effectiveness are prioritized. In addition, the regulatory landscape is evolving with stricter oversight on opioid prescribing, while government incentives are fostering innovation in pain management therapies. This combination of regulatory support, technological advancements, and a focus on non-opioid treatments is shaping the future of the chronic pain market in France.

Market Challenges Analysis

Underdiagnosis, Undertreatment, and Access to Care Challenges

A major challenge in managing chronic pain in France is the underdiagnosis and undertreatment of patients. Many individuals, particularly in rural areas, are unaware of chronic pain conditions and the available treatment options, leading to delayed diagnosis. Additionally, the social stigma associated with chronic pain often prevents patients from seeking help, further exacerbating the issue. This is compounded by healthcare providers who may have limited awareness or training in recognizing and treating chronic pain effectively. As a result, patients often do not receive the appropriate care in a timely manner. Geographic disparities in healthcare access also play a significant role in these challenges. In rural areas, specialized pain clinics and healthcare professionals are less accessible, leading to long wait times for appointments and treatments. For instance, there are 245 pain consultations or centers in France, with a significant portion located in urban areas. These delays can cause frustration and worsen the patient’s condition. Despite having a robust healthcare system, the pressure on resources often leads to constraints, making it difficult for patients to access timely and effective pain management.

Opioid Crisis, Non-Pharmacological Barriers, and Patient Engagement Issues

The ongoing opioid crisis and increased regulatory scrutiny on opioid prescribing present another challenge for chronic pain patients in France. While opioids remain an important treatment option for severe pain, concerns about addiction and misuse have led to a more cautious approach in prescribing these medications. For instance, the use of strong opioids like oxycodone increased by 738% between 2006 and 2017, raising concerns about addiction and overdose. This caution can sometimes hinder access to pain relief for patients who require opioids for proper management. Simultaneously, there are barriers to non-pharmacological treatments, such as physical therapy, acupuncture, and psychological interventions. These therapies, though effective, are often in limited supply and may not be adequately covered by reimbursement policies, limiting patient access. Furthermore, patient adherence to treatment regimens remains a significant hurdle. Chronic pain management often involves complex treatment plans, including medication schedules and lifestyle changes, which can be challenging for patients to follow. Inadequate education on chronic pain management strategies also impedes patients’ ability to self-manage their condition, ultimately affecting their engagement and overall treatment outcomes. These challenges collectively impact the overall effectiveness of chronic pain management in France.

Market Opportunities

Rising Demand for Non-Opioid Pain Management Solutions

The growing concerns about opioid addiction and misuse present a significant market opportunity for non-opioid pain management therapies in France. As the healthcare system increasingly focuses on reducing opioid prescriptions, there is a strong demand for alternative treatments. Non-pharmacological interventions such as physical therapy, acupuncture, and mindfulness practices, along with emerging non-opioid pharmaceuticals, are gaining traction as effective solutions for chronic pain management. Companies developing novel analgesics, neuromodulation devices, and targeted therapies have a clear opportunity to capitalize on this shift. Additionally, advancements in digital health technologies, such as remote pain monitoring tools and telehealth consultations, present opportunities to improve patient access and engagement in chronic pain management, particularly in rural areas where specialized care may be limited.

Government Support and Evolving Regulatory Landscape

France’s healthcare system is adapting to the increasing burden of chronic pain, providing market opportunities for innovative treatment solutions. The French government’s support for research and development in pain management therapies, coupled with favorable reimbursement policies for effective treatments, creates a conducive environment for market growth. Regulatory changes encouraging the development of new pain management drugs and devices, alongside the rising focus on value-based healthcare, further enhance these opportunities. As the population ages and the prevalence of chronic pain conditions rises, there is a growing need for more personalized and comprehensive treatment options. This creates significant growth potential for pharmaceutical companies, medical device manufacturers, and digital health innovators who can meet the evolving demands of patients and healthcare providers in managing chronic pain.

Market Segmentation Analysis:

By Indication:

The chronic pain market in France is primarily segmented by indication, with neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraines being the most prevalent conditions. Neuropathic pain, which includes conditions such as diabetic neuropathy and post-surgical pain, holds a significant share of the market due to its complex nature and the increasing aging population. Arthritis pain, driven by conditions like osteoarthritis and rheumatoid arthritis, is another major contributor, particularly among the elderly. Chronic back pain is widespread, often linked to sedentary lifestyles and age-related degeneration. Cancer pain, although less prevalent, remains a crucial area due to the rising cancer incidence and the complex management of pain in palliative care settings. Migraine, which affects a large portion of the working-age population, further contributes to the market’s growth. As awareness increases and treatment options become more specialized, these conditions will continue to drive demand for effective pain management therapies in the French market.

By Drug Class:
The French chronic pain market is also segmented by drug class, with opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and emerging therapies playing key roles. Opioids have traditionally been the cornerstone of pain management, particularly for severe cases of cancer and chronic back pain; however, the ongoing opioid crisis has led to a shift towards alternative therapies. NSAIDs remain widely used for managing arthritis and back pain, offering anti-inflammatory and analgesic effects, but concerns over long-term use and side effects are pushing the demand for safer alternatives. Anticonvulsants, such as pregabalin and gabapentin, are increasingly used for neuropathic pain, providing effective relief for conditions like diabetic neuropathy. Antidepressants, particularly tricyclics and serotonin-norepinephrine reuptake inhibitors (SNRIs), are utilized in the treatment of neuropathic and chronic pain syndromes. As new drug classes and non-pharmacological treatments continue to evolve, the market will see an increasing shift towards multi-modal approaches that offer both efficacy and reduced side effects.

Segments:

Based on Indication:

Neuropathic Pain
Arthritis Pain
Chronic Back Pain
Cancer Pain
Migraine

Based on Drug Class:

Opioids
Non-Steroidal
Anticonvulsants
Antidepressants
Drug Class 5

Based on Application:

Musculoskeletal
Neuropathy
Oncology
Others
End-user 5

Based on Technology:

Technology 1
Technology 2
Technology 3

Based on Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others
Distribution Channel 4
Distribution Channel 5

Based on the Geography:

Northern France
Southern France
Eastern France
Western France

Regional Analysis

Northern France

Northern France holds a significant share of the chronic pain market, accounting for approximately 40% of the overall market. The region is home to a large population with a notable prevalence of chronic pain conditions, driven by factors such as the aging population, high rates of lifestyle-related diseases, and the growing awareness of pain management options. The presence of well-established healthcare infrastructure, particularly in urban centers like Paris and Lille, plays a crucial role in meeting the demand for pain management treatments. Specialized pain management clinics and healthcare professionals are more concentrated in this region, providing patients with a wide range of therapies, including pharmacological and non-pharmacological options. Additionally, the rising trend towards digital health tools, including telehealth services and remote monitoring, has further bolstered the growth of the chronic pain market in Northern France. The region’s strong focus on healthcare innovation, along with government support for research into pain management solutions, ensures that Northern France continues to be a key player in the overall market growth.

Southern France
Southern France, accounting for approximately 35% of the market share, presents a distinct regional opportunity for the chronic pain market. The region, known for its active lifestyle and warmer climate, sees a higher incidence of chronic pain conditions related to musculoskeletal issues, particularly in the elderly population. Conditions such as arthritis, back pain, and fibromyalgia are prevalent due to lifestyle factors and the aging demographic. With cities like Marseille and Nice serving as hubs for healthcare and medical tourism, the demand for advanced pain management solutions continues to grow. The availability of specialized clinics and pain management professionals in these urban areas, combined with increasing awareness among patients, has led to a rising demand for both traditional pain medications and innovative treatments, including neuromodulation and alternative therapies. Southern France also benefits from government initiatives aimed at improving healthcare access, especially in rural areas, where long travel times often deter patients from seeking timely care. This regional focus on both innovation and accessibility, along with the shift toward non-opioid therapies, positions Southern France as a crucial market for chronic pain management in the coming years.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Abbott Laboratories
Company 2
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Remedee Labs
SUBLIMED
Grünenthal
Company 12
Company 13
Company 14

Competitive Analysis

The competitive landscape of the France chronic pain market is marked by the presence of leading global and emerging players. Key players include Abbott Laboratories, Grünenthal, Remedee Labs, SUBLIMED, and others. Companies in the market are adopting strategies such as product diversification, research and development, and strategic collaborations to enhance their competitive edge. The growing demand for non-opioid therapies has led to a shift towards the development of safer, more effective treatments, particularly in response to concerns over opioid addiction. The market is also witnessing an increasing emphasis on digital health solutions and neuromodulation technologies. These advancements offer personalized, non-invasive options for chronic pain management, which are gaining popularity among patients seeking alternatives to traditional treatments. Additionally, companies are focusing on expanding their regional presence, especially in urban areas where healthcare infrastructure is more developed, while also addressing the gaps in rural regions with limited access to specialized care. With the rising prevalence of chronic pain, the competition is intensifying, and market players are investing heavily in clinical trials, regulatory approvals, and collaborations with healthcare providers to improve patient outcomes. The evolving nature of the market, along with the increasing focus on patient-centric solutions, ensures continued growth and innovation within the chronic pain management space in France.

Recent Developments

In July 2024, Boston Scientific Corporation announced positive five-year results for the Intracept Intraosseous Nerve Ablation System, presented at the American Society of Pain & Neuroscience (ASPN) conference in Miami Beach, Florida. The data, pooled from three clinical trials, highlight the effectiveness of the Intracept system in treating vertebrogenic low back pain, a condition caused by damage to vertebral endplates.
In April 2024, Vertex Pharmaceuticals announced significant progress in its suzetrigine pain program, an oral selective NaV1.8 pain signal inhibitor that is poised to become the first new class of medicine for acute and neuropathic pain in over two decades. Following positive Phase 3 results in January 2024, the FDA granted New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
In February 2024, CinCor Pharma, Inc. was acquired by AstraZeneca. Cincor is a clinical stage biopharmaceutical company based out of USA that is focused on developing novel treatments for severe hypertension and chronic kidney disease.
In January 2024, Bayer AG disclosed its plan to strengthen its pharmaceutical and consumer health businesses. This move will bolster the company’s American market presence.
In January 2024, Sanofi announced its acquisition of Inhibrx, Inc., aiming to incorporate a potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency into its pipeline.
In December 2023, Forever Cheer, a pharmaceutical company holding more than 10 global patents, selected Hong Kong as the launchpad for its innovative pain management drugs, aiming to expand its global footprint and significantly impact the healthcare industry
In August 2023, MOBE and Override, digital health innovators, partnered to introduce a shared savings program for chronic pain management. This initiative focuses on providing personalized pain treatment through data analytics and behavioral health coaching, with the goal of reducing healthcare costs.

Market Concentration & Characteristics

The France chronic pain market exhibits moderate to high market concentration, with a few leading players holding a significant share, while numerous emerging companies are actively contributing to the market’s growth. The market is characterized by a diverse range of treatment options, including pharmaceutical drugs, neuromodulation devices, and digital health solutions. Established pharmaceutical companies continue to dominate the market, with a strong focus on research and development of novel pain management therapies. However, the increasing demand for non-opioid treatments and personalized care is giving rise to new players who are introducing innovative, non-invasive therapies such as neuromodulation and digital health platforms. The market is also shaped by a growing awareness of chronic pain and its management, which has led to greater patient demand for effective and safer therapies. As a result, companies are investing in product diversification, clinical trials, and regulatory approvals to stay competitive. The shift towards value-based healthcare models is another key characteristic, with a focus on improving patient outcomes while managing healthcare costs. Geographic disparities in access to care, particularly in rural regions, influence market dynamics, as companies aim to address these gaps by expanding their regional presence. Overall, the French chronic pain market is becoming increasingly competitive and patient-centric, with significant opportunities for innovation and growth.

Report Coverage

The research report offers an in-depth analysis based on Indication, Drug Class, Application, Technology, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The France chronic pain market is expected to grow at a steady pace, driven by an increasing aging population and rising prevalence of chronic pain conditions.
There will be a continued shift towards non-opioid therapies due to growing concerns over opioid addiction.
Advancements in digital health tools and telemedicine will improve patient access to chronic pain management.
The development of neuromodulation devices and personalized treatments will offer innovative solutions for managing chronic pain.
Increased awareness about chronic pain and its impact on quality of life will lead to higher demand for effective therapies.
The expansion of non-pharmacological treatments such as physical therapy, acupuncture, and mindfulness will gain traction.
Growing focus on value-based healthcare models will prioritize patient outcomes and cost-effectiveness in pain management.
Government initiatives and healthcare reforms will improve access to pain management treatments, especially in underserved areas.
Increased investment in research and development will drive innovation in chronic pain therapies.
The regulatory environment in France will continue to evolve, encouraging new treatment options while ensuring patient safety.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. CHRONIC PAIN Market Snapshot 21

2.1.1. France CHRONIC PAIN Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : CHRONIC PAIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by France 32

5.1.1. France CHRONIC PAIN Market Import Volume/Revenue, By France, 2018 – 2023 32

5.2. Export Analysis by France 33

5.2.1. France CHRONIC PAIN Market Export Volume/Revenue, By France, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by France 34

6.1.1. France CHRONIC PAIN Market Demand Volume/Revenue, By France, 2018 – 2023 34

6.2. Supply Analysis by France 35

6.2.1. France CHRONIC PAIN Market Supply Volume/Revenue, By France, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by France 36

7.1.1. France CHRONIC PAIN Market Production Volume/Revenue, By France, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Indication 37

8.1.1. France CHRONIC PAIN Market Price, By Indication, 2018 – 2023 37

8.1.2. France Indication Market Price, By Indication, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. France CHRONIC PAIN Market: Company Market Share, by Volume, 2023 40

11.1.2. France CHRONIC PAIN Market: Company Market Share, by Revenue, 2023 41

11.1.3. France CHRONIC PAIN Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. France CHRONIC PAIN Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. France CHRONIC PAIN Market Company Volume Market Share, 2023 43

11.3. France CHRONIC PAIN Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

France Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : CHRONIC PAIN MARKET – BY INDICATION SEGMENT ANALYSIS 49

13.1. CHRONIC PAIN Market Overview, by Indication Segment 49

13.1.1. CHRONIC PAIN Market Revenue Share, By Indication, 2023 & 2032 50

13.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Indication 51

13.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 51

13.1.4. CHRONIC PAIN Market Revenue, By Indication, 2018, 2023, 2027 & 2032 52

13.2. Neuropathic Pain 53

13.3. Arthritis pain 54

13.4. Chronic Back pain 55

13.5. Cancer Pain 56

13.6. Migraine 57

CHAPTER NO. 14 : CHRONIC PAIN MARKET – BY DRUG CLASS SEGMENT ANALYSIS 58

14.1. CHRONIC PAIN Market Overview, by Drug Class Segment 58

14.1.1. CHRONIC PAIN Market Revenue Share, By Drug Class , 2023 & 2032 59

14.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Drug Class 60

14.1.3. Incremental Revenue Growth Opportunity, by Drug Class , 2024 – 2032 60

14.1.4. CHRONIC PAIN Market Revenue, By Drug Class , 2018, 2023, 2027 & 2032 61

14.2. Opiods 62

14.3. Non steroidal 63

14.4. Anticonvulsants 64

14.5. Antidepressants: 65

14.6. Drug Class 5 66

CHAPTER NO. 15 : CHRONIC PAIN MARKET – BY APPLICATION ANALYSIS 67

15.1. CHRONIC PAIN Market Overview, by Application 67

15.1.1. CHRONIC PAIN Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. CHRONIC PAIN Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. CHRONIC PAIN Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Musculoskeletal 71

15.3. Neuropathy 72

15.4. Oncology 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : CHRONIC PAIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. CHRONIC PAIN Market Overview, by Technology Segment 76

16.1.1. CHRONIC PAIN Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. CHRONIC PAIN Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. CHRONIC PAIN Market Overview, by Distribution Channel Segment 83

17.1.1. CHRONIC PAIN Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. CHRONIC PAIN Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. CHRONIC PAIN Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Retail Pharmacies 88

17.4. Others 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : CHRONIC PAIN MARKET – FRANCE ANALYSIS 92

18.1. Indication 92

18.1.1. France CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 (USD Million) 92

18.2. France CHRONIC PAIN Market Revenue, By Indication, 2024 – 2032 (USD Million) 92

18.3. Drug Class 93

18.3.1. France CHRONIC PAIN Market Revenue, By Drug Class , 2018 – 2023 (USD Million) 93

18.3.2. France CHRONIC PAIN Market Revenue, By Drug Class , 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. France CHRONIC PAIN Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. France CHRONIC PAIN Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. France CHRONIC PAIN Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. France CHRONIC PAIN Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. France CHRONIC PAIN Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. France CHRONIC PAIN Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Abbott Laboratories 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. Company 2 99

19.1.7. Company 3 99

19.1.8. Company 4 99

19.1.9. Company 5 99

19.1.10. Company 6 99

19.1.11. Company 7 99

19.1.12. Company 8 99

19.1.13. Remedee Labs 99

19.1.14. SUBLIMED. 99

19.1.15. Grünenthal 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. France CHRONIC PAIN Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for France CHRONIC PAIN Market 29

FIG NO. 3. Value Chain Analysis for France CHRONIC PAIN Market 30

FIG NO. 4. France CHRONIC PAIN Market Import Volume/Revenue, By France, 2018 – 2023 32

FIG NO. 5. France CHRONIC PAIN Market Export Volume/Revenue, By France, 2018 – 2023 33

FIG NO. 6. France CHRONIC PAIN Market Demand Volume/Revenue, By France, 2018 – 2023 34

FIG NO. 7. France CHRONIC PAIN Market Supply Volume/Revenue, By France, 2018 – 2023 35

FIG NO. 8. France CHRONIC PAIN Market Production Volume/Revenue, By France, 2018 – 2023 36

FIG NO. 9. France CHRONIC PAIN Market Price, By Indication, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. CHRONIC PAIN Market – Company Volume Market Share, 2023 43

FIG NO. 18. CHRONIC PAIN Market – Company Revenue Market Share, 2023 44

FIG NO. 19. CHRONIC PAIN Market Revenue Share, By Indication, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Indication 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 51

FIG NO. 22. CHRONIC PAIN Market Revenue, By Indication, 2018, 2023, 2027 & 2032 52

FIG NO. 23. France CHRONIC PAIN Market for Neuropathic Pain, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. France CHRONIC PAIN Market for Arthritis pain, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. France CHRONIC PAIN Market for Chronic Back pain , Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. France CHRONIC PAIN Market for Cancer Pain, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. France CHRONIC PAIN Market for Migraine, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. CHRONIC PAIN Market Revenue Share, By Drug Class , 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Drug Class 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Drug Class , 2024 – 2032 60

FIG NO. 31. CHRONIC PAIN Market Revenue, By Drug Class , 2018, 2023, 2027 & 2032 61

FIG NO. 32. France CHRONIC PAIN Market for Opiods, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. France CHRONIC PAIN Market for Non steroidal , Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. France CHRONIC PAIN Market for Anticonvulsants, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. France CHRONIC PAIN Market for Antidepressants:, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. France CHRONIC PAIN Market for Drug Class 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. CHRONIC PAIN Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. CHRONIC PAIN Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. France CHRONIC PAIN Market for Musculoskeletal, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. France CHRONIC PAIN Market for Neuropathy, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. France CHRONIC PAIN Market for Oncology, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. France CHRONIC PAIN Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. France CHRONIC PAIN Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. CHRONIC PAIN Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. CHRONIC PAIN Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. France CHRONIC PAIN Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. France CHRONIC PAIN Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. France CHRONIC PAIN Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. CHRONIC PAIN Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. CHRONIC PAIN Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. France CHRONIC PAIN Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. France CHRONIC PAIN Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. France CHRONIC PAIN Market for Others, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. France CHRONIC PAIN Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. France CHRONIC PAIN Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : France CHRONIC PAIN Market: Snapshot 18

TABLE NO. 2. : Drivers for the CHRONIC PAIN Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the CHRONIC PAIN Market: Impact Analysis 24

TABLE NO. 4. : France CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : France CHRONIC PAIN Market Revenue, By Indication, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : France CHRONIC PAIN Market Revenue, By Indication, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : France CHRONIC PAIN Market Revenue, By Drug Class , 2018 – 2023 (USD Million) 90

TABLE NO. 9. : France CHRONIC PAIN Market Revenue, By Drug Class , 2024 – 2032 (USD Million) 90

TABLE NO. 10. : France CHRONIC PAIN Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : France CHRONIC PAIN Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : France CHRONIC PAIN Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : France CHRONIC PAIN Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : France CHRONIC PAIN Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : France CHRONIC PAIN Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the France Chronic Pain Market?

The France chronic pain market was valued at USD 3,088.37 million in 2023 and is projected to grow to USD 4,937.10 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.15%.

What factors are driving the growth of the France Chronic Pain Market?

Key factors include the rising prevalence of chronic pain conditions such as arthritis and neuropathic pain, an aging population, advancements in pharmacological and non-pharmacological treatments, and growing awareness about the impact of chronic pain on quality of life. The adoption of digital health technologies and government healthcare reforms also contribute to market growth.

What are the key segments within the France Chronic Pain Market?

The market is segmented by indication (neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraine), drug class (opioids, NSAIDs, anticonvulsants, antidepressants, and emerging therapies), application (musculoskeletal, neuropathy, oncology, and others), and distribution channels (hospital pharmacies, retail pharmacies, and others).

What are some challenges faced by the France Chronic Pain Market?

Challenges include underdiagnosis and undertreatment of chronic pain, limited access to specialized care in rural areas, the ongoing opioid crisis, barriers to non-pharmacological treatments, and patient adherence to complex treatment regimens.

Who are the major players in the France Chronic Pain Market?

Key players include Abbott Laboratories, Grünenthal, Remedee Labs, SUBLIMED, and other emerging companies focusing on innovative therapies, neuromodulation devices, and digital health solutions to enhance chronic pain management.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –